These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. SGK1 inhibition attenuated the action potential duration in patient- and genotype-specific re-engineered heart cells with congenital long QT syndrome. Kim M; Das S; Tester DJ; Pradhananga S; Hamrick SK; Gao X; Srinivasan D; Sager PT; Ackerman MJ Heart Rhythm O2; 2023 Apr; 4(4):268-274. PubMed ID: 37124559 [TBL] [Abstract][Full Text] [Related]
3. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. Ma D; Wei H; Zhao Y; Lu J; Li G; Sahib NB; Tan TH; Wong KY; Shim W; Wong P; Cook SA; Liew R Int J Cardiol; 2013 Oct; 168(6):5277-86. PubMed ID: 23998552 [TBL] [Abstract][Full Text] [Related]
4. Gating Properties of Mutant Sodium Channels and Responses to Sodium Current Inhibitors Predict Mexiletine-Sensitive Mutations of Long QT Syndrome 3. Li G; Woltz RL; Wang CY; Ren L; He PX; Yu SD; Liu XQ; Yarov-Yarovoy V; Hu D; Chiamvimonvat N; Wu L Front Pharmacol; 2020; 11():1182. PubMed ID: 32848785 [TBL] [Abstract][Full Text] [Related]
5. Phenotypic characterization of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel. Kambouris NG; Nuss HB; Johns DC; Tomaselli GF; Marban E; Balser JR Circulation; 1998 Feb; 97(7):640-4. PubMed ID: 9495298 [TBL] [Abstract][Full Text] [Related]
6. Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies. Stutzman MJ; Gao X; Kim M; Ye D; Zhou W; Tester DJ; Giudicessi JR; Shannon K; Ackerman MJ Heart Rhythm; 2023 May; 20(5):709-717. PubMed ID: 36731785 [TBL] [Abstract][Full Text] [Related]
7. Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction. Malan D; Zhang M; Stallmeyer B; Müller J; Fleischmann BK; Schulze-Bahr E; Sasse P; Greber B Basic Res Cardiol; 2016 Mar; 111(2):14. PubMed ID: 26803770 [TBL] [Abstract][Full Text] [Related]
9. Patient-specific iPSC-derived cardiomyocytes reveal aberrant activation of Wnt/β-catenin signaling in SCN5A-related Brugada syndrome. Cai D; Wang X; Sun Y; Fan H; Zhou J; Yang Z; Qiu H; Wang J; Su J; Gong T; Jiang C; Liang P Stem Cell Res Ther; 2023 Sep; 14(1):241. PubMed ID: 37679791 [TBL] [Abstract][Full Text] [Related]
10. Na Pierre M; Djemai M; Poulin H; Chahine M Sci Rep; 2021 Aug; 11(1):17168. PubMed ID: 34433864 [TBL] [Abstract][Full Text] [Related]
11. Patient-specific, re-engineered cardiomyocyte model confirms the circumstance-dependent arrhythmia risk associated with the African-specific common SCN5A polymorphism p.S1103Y: Implications for the increased sudden deaths observed in black individuals during the COVID-19 pandemic. Hamrick SK; John Kim CS; Tester DJ; Giudicessi JR; Ackerman MJ Heart Rhythm; 2022 May; 19(5):822-827. PubMed ID: 34979239 [TBL] [Abstract][Full Text] [Related]
12. Anti-arrhythmic potential of the late sodium current inhibitor GS-458967 in murine Scn5a-1798insD+/- and human SCN5A-1795insD+/- iPSC-derived cardiomyocytes. Portero V; Casini S; Hoekstra M; Verkerk AO; Mengarelli I; Belardinelli L; Rajamani S; Wilde AAM; Bezzina CR; Veldkamp MW; Remme CA Cardiovasc Res; 2017 Jun; 113(7):829-838. PubMed ID: 28430892 [TBL] [Abstract][Full Text] [Related]
13. Differential modulation of late sodium current by protein kinase A in R1623Q mutant of LQT3. Tsurugi T; Nagatomo T; Abe H; Oginosawa Y; Takemasa H; Kohno R; Makita N; Makielski JC; Otsuji Y Life Sci; 2009 Mar; 84(11-12):380-7. PubMed ID: 19167409 [TBL] [Abstract][Full Text] [Related]
14. Translation reinitiation in c.453delC frameshift mutation of KCNH2 producing functional hERG K+ channels with mild dominant negative effect in the heterozygote patient-derived iPSC cardiomyocytes. Park NK; Park SJ; Park YG; Moon SH; Woo J; Kim HJ; Kim SJ; Choi SW Hum Mol Genet; 2024 Jan; 33(2):110-121. PubMed ID: 37769355 [TBL] [Abstract][Full Text] [Related]
15. Switch From Fetal to Adult Veerman CC; Mengarelli I; Lodder EM; Kosmidis G; Bellin M; Zhang M; Dittmann S; Guan K; Wilde AAM; Schulze-Bahr E; Greber B; Bezzina CR; Verkerk AO J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28739862 [TBL] [Abstract][Full Text] [Related]
16. A de novo missense mutation of human cardiac Na+ channel exhibiting novel molecular mechanisms of long QT syndrome. Makita N; Shirai N; Nagashima M; Matsuoka R; Yamada Y; Tohse N; Kitabatake A FEBS Lett; 1998 Feb; 423(1):5-9. PubMed ID: 9506831 [TBL] [Abstract][Full Text] [Related]
18. Intrinsic mechanism of the enhanced rate-dependent QT shortening in the R1623Q mutant of the LQT3 syndrome. Oginosawa Y; Nagatomo T; Abe H; Makita N; Makielski JC; Nakashima Y Cardiovasc Res; 2005 Jan; 65(1):138-47. PubMed ID: 15621041 [TBL] [Abstract][Full Text] [Related]
19. In utero onset of long QT syndrome with atrioventricular block and spontaneous or lidocaine-induced ventricular tachycardia: compound effects of hERG pore region mutation and SCN5A N-terminus variant. Lin MT; Wu MH; Chang CC; Chiu SN; Thériault O; Huang H; Christé G; Ficker E; Chahine M Heart Rhythm; 2008 Nov; 5(11):1567-74. PubMed ID: 18848812 [TBL] [Abstract][Full Text] [Related]
20. Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients. Hu RM; Tester DJ; Li R; Sun T; Peterson BZ; Ackerman MJ; Makielski JC; Tan BH Channels (Austin); 2018; 12(1):176-186. PubMed ID: 29983085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]